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CLINICAL FEATURES AND VISUAL OUTCOME IN 
PAEDIATRIC OPTIC NEURITIS 
  
Introduction 
 Optic neuritis is defined as the idiopathic, demyelinating, 
inflammation of the optic nerve, characterised by sudden mono ocular 
vision loss, ipsilateral eye pain and dyschromatopsia. When compared to 
its adult counterpart, pediatric optic neuritis is different in its clinical 
manifestations and future neurological sequelae. In children, bilateral 
type is more common than unilateral, anterior is more common than 
posterior, pain with ocular movements is less likely, the initial vision loss 
is profound and the final visual acuity gain is very drastic when compared 
to adults. 
Epidemiology 
 Optic neuritis is more common in women(female to male ratio- 
5:1), between the age group of 18-45 years. It is more common in 
Caucasians. Asians and Africans are least susceptible. Incidence is 
around 5 per 1,00,000 population in adults, when compared to 0.2% per 
1,00,000 population in children(1). 
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Etiology 
1) Idiopathic 
2) Multiple sclerosis  
Optic neuritis occurs in about 50% of patients with MS and is the 
presenting feature in about 20% of patients2-5. Recurrent optic neuritis is 
more common with MS, which may involve the same eye or the fellow 
eye 2-5. The optic neuritis treatment trial has shown that female gender, 
one or more lesions on MRI, history of non specific neurological 
symptoms(usually transient numbness), prior optic neuritis in fellow eye 
or retro bulbar optic neuritis are positive risk factors for the development 
of multiple sclerosis6. Negative risk factors include male gender, no 
lesions on MRI, optic disc swelling, absence of pain and 
ophthalmoscopic findings of severe optic disc edema, peri papillary 
haemorrhages or retinal exudates6. 
ONTT has shown that the 10 year risk of development of multiple 
sclerosis is 38% in patients with idiopathic optic neuritis. Patients who 
had 1 or more typical lesions on the baseline MRI had a 56% risk; those 
with no lesions had a risk of 22% and it was also demonstrated that, 
higher number of lesions do not appreciably increase that risk2. 
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3) Neuro myelitis optica (Devic’s disease) 
An inflammatory demyelinating  disease of the CNS – a variant of 
multiple sclerosis, characterised by bilateral optic neuritis and transverse 
myelitis, with a propensity for children and young adults. The optic 
nerves, the spinal cord and less frequently the cerebrum are affected by 
scattered lesions of demyelination, that principally affect the white 
matter, with widespread destruction of myelin sheaths7-10. 
The primary features of neuro myelitis optica are visual loss caused 
by damage to the anterior visual sensory pathways and paraplegia caused 
by damage to the spinal cord. It is often preceded by a prodrome of sore 
throat, fever and headache or rarely antecedent viral illness or of a recent 
viral vaccination. There is rapid, severe visual loss which is most 
frequently bilateral although one eye is affected first, while the second 
eye is affected within hours to days. This is in contrast to typical optic 
neuritis where visual loss is less severe and often unilateral. Although few 
patients develop permanent, severe visual loss in both eyes, most patients 
show some visual recovery within a few weeks to months of the disease 
onset. Visual fields also show gradual recovery. 
4) Viral and bacterial infections 
Direct infection of the nerve (viral or bacterial) or inflammation 
triggered by an auto immune reaction to a systemic or central nervous 
infection may cause optic neuritis. Etiology includes viruses like adeno 
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virus, coxsackie virus, CMV, hepatitis a virus, EBV, HIV and the 
measles, mumps, rubella and varicella zoster viruses. Bacterial infections 
include syphilis, Lyme’s disease, cat scratch disease, anthrax, β 
haemolytic strepto coccal infection, brucellosis, meningo coccal 
infection, TB, typhoid fever and Whipple’s disease. Optic neuritis 
usually occurs within 1 to 3 weeks of the basic infection11-13.  
5) Post vaccination optic neuritis 
Optic neuritis can occur after vaccination against both bacterial and 
viral infections like BCG, hepatitis B virus, rabies virus, tetanus toxoid, 
DPT & MMR. Influenza virus is most commonly associated with such 
presentation. The onset is usually within 1 to 3 weeks, being most 
commonly bilateral and of the anterior variety. Visual recovery occurs 
over few weeks to months 14-16. 
6) Inflammatory optic neuritis 
Granulomatous inflammation of the optic nerve occurs in certain 
diseases such as sarcoidosis, tuberculosis and leprosy, where this 
manifestation may be the first clinical feature of the disease process, but 
more often occurs during the course of the disease. The appearance of 
the optic disc is characteristic, with a lumpy white appearance. 
Inflammatory reaction in the vitreous or the anterior chamber may 
accompany the optic neuritis. Classical response to therapy with cortico 
steroids is seen in an inflammatory etiology, unlike in cases with 
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demyelination. Visual recovery is rapid, which may decline when dose is 
tapered or stopped. This feature is more typical of inflammatory 
pathology.(17-20) 
7) Parasitic infestation- toxoplasma, toxocara, sandfly fever 
8) Fungal infection- aspergillosis, crypto coccosis 
9) Contiguous inflammation from meninges, orbit and sinuses 
10) Unusual retinal diseases- DUSN, APMPPE, MEWDS 
11) Severe pyogenic and orbital infections 
12) Diabetes mellitus 
13) Takayasu arteritis 
14) Carotid vascular insufficiency 
15) Athero sclerosis 
16) Collagen vascular diseases 
Pathophysiology 
Lesions of the optic nerve in idiopathic and multiple sclerosis-
related optic neuritis are similar to the plaques seen in multiple sclerosis 
of the brain. In acute optic neuritis, the lesions are sharply defined areas 
of myelin sheath loss, with relative preservation of the axons. Large 
numbers of foamy macrophages exist, with cholesterol ester droplets & 
abundant lymphocyte and plasma cell accumulations. 
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In later stages of the disease, the numbers of lymphocytes, plasma 
cells, and macrophages diminish & astrocytic scar formation occurs. 
Little remyelination of the damaged axons in lesions is associated with 
chronic multiple sclerosis, but evidence exists of oligo dendrocyte 
precursor cells and remyelination attempts in early multiple sclerosis and 
acute lesions. This suggests that potential therapeutic interventions that 
promote myelin formation, can play a role in improved recovery. (21-24)  
Various genetic & environmental factors are presumed to 
predispose patients to demyelination as an auto immune response. The 
presence of alleles for human leucocyte antigen DW2 (HLA – DW2) or 
human leucocyte antigen DR2 (HLA – DR2) is a known risk factor in the 
development of optic neuritis and multiple sclerosis. Viral or bacterial 
infection, stress and systemic antigens and metabolites have been 
proposed as possible initiating events, that result in auto reactive 
antibodies and T cells crossing the blood brain barrier, causing a delayed 
type IV hypersensitivity reaction and injuring myelin.(21-24) 
The most common site of involvement of optic nerve in optic 
neuritis in decreasing order of frequency :(21-24) 
1) Anterior (45%), abutting the optic disc 
2) Mid- intra orbital (61%) 
3) Intra canalicular (34%) 
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4) Intra cranial pre chiasmatic (5%) and 
5) Chiasmatic segments (2%) 
Classification 
a) Ophthalmoscopically: 
Papillitis 
Retro bulbar neuritis 
Neuro retinitis 
b) Etiologically: 
Demyelinating 
Para infectious 
Infectious 
c) Structurally: 
Peri neuritis or peripheral optic neuritis 
Axial neuritis 
Clinical features 
Optic neuritis can be symptomatic or asymptomatic. When 
symptomatic, it presents with the classical triad of loss of vision, 
ipsilateral eye pain and dyschromatopsia. Associated symptoms might be 
movement phosphenes, sound induced phosphenes, visual obscuration in 
bright light and Uhthoff’s phenomenon. A relative afferent papillary 
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defect is nearly always present in unilateral and bilateral asymmetric 
cases. 
Loss of vision 
Occurs as an isolated symptom in 55% of cases. 
Rate of failing vision varies- within hours(29%), within 1 to 2 
days(20%), within 3 to 7 days(23%) or within one to two weeks(7%). 
The drop is initially unstable, then stabilises and then improves. 
The severity varies from mild to severe( perception or no 
perception of light). 
Pain 
 It may either accompany or precede the visual loss(25). It can be 
generalised headache or headache in involved eye region. 
The pain is dull aching in nature. 
The maximal severity occurs in 24-36 hours and spontaneously 
abates in 48-72 hours. 
Pain may be due to traction of the origin of medial and superior 
recti on the optic nerve sheath at the orbital apex, especially in retro 
bulbar neuritis (Whitnall’s hypothesis)(26). 
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Dyschromatopsia 
 Impaired colour vision is always present in optic neuritis. Patient 
observes a reduced vividness of saturated colours. In absence of macular 
lesion, colour desaturation is highly sensitive indicator of optic nerve 
dysfunction. 
Movement phosphenes 
 It can occur before an attack of optic neuritis or may accompany 
visual loss during the attack, or may occur 6 months after full recovery. 
These occur especially in horizontal movements in dimly lit room- 
lasting only for 1 or 2 seconds, occurring unilaterally and in ipsilateral 
affected eye, even when it is maintained in lateral gaze. 
In optic neuritis, it is due to demyelination and demyelinated nerve 
fibres may discharge spontaneously when subjected to minimal 
mechanical stress. 
Sound induced phosphenes 
 They can be precipitated by sudden noise and can occur in diseases 
of eye or optic nerve including optic neuritis and compressive optic 
neuropathy. 
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Visual obscuration in bright light 
It may be due to fluctuating interference in the transmission of 
visual signals- the site may be at the level of demyelinated visual 
pathway. 
Uhthoff’s symptom 
 It is an episodic obscuration of vision with exertion, hot baths and 
showers in 49.5% of patients with isolated optic neuritis and may be 
correlated with a higher incidence and recurrence of optic neuritis(27). 
Typically the patient has blurring of vision in the affected eye after 
5 to 20 minutes of exposure to the provoking factor.Colour desaturation 
may also occur. 
After resting or moving away from heat, vision recovers to its 
previous level within 5 to 60 minutes. 
It correlates significantly with multi focal white matter lesions on 
brain MRI.It can be detected by Fansworth Munsell 100 hue testing and 
Octopus perimetry, as well as by fluctuations in VEP amplitudes and 
contrast sensitivity. 
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Signs 
1) Reduced visual acuity: 
It can be variable from 6/9 to no perception of light. 
The severity can be assessed with Graded visual impairment scale in 
optic neuritis. 
2) Pupillary reaction 
Relative afferent papillary defect (Marcus Gunn pupil) is a highly 
sensitive sign of optic nerve lesion. The unilateral RAPD can be 
roughly quantified by use of graded density filters. The filter density is 
placed in front of the normal eye and is used to balance the defect in 
the other eye. This can be used to measure the disease progression(28). 
3) Dyschromatopsia 
Impaired colour vision is always present in optic neuritis. In the 
absence of a macular lesion, colour desaturation is a highly sensitive 
indicator of optic nerve disease. Colour vision – a parvo cellular – 
ganglion cell function, is abnormal in patients with acute and 
recovered optic neuritis.  
Colour vision defects are highly sensitive indicators of a previous 
attack of optic neuritis. Typically, the patient observes a reduced 
vividness of saturated colours. Saturation refers to the purity of colour, 
while desaturation is the degree to which a colour is mixed with white. 
12 
 
Colour vision tested by Fansworth Munsell 100 Hue test(FM 100) 
or Ishihara / Hardy Rand Ritter pseudo isochromatic plates is 
always impaired and was supposed to be essentially red green 
deficiency. But it has been found that there is no evidence of a 
wavelength specific defect in FM polar diagrams, but significant 
bipolar abnormality in the tritan(blue-yellow) axis present at 
presentation, but not on subsequent visits(29). 
Recent studies show, blue-yellow defects tend to be slightly more 
common in the acute phase of the disease, with slightly more red-green 
defects at 6 months. Persons may shift defect type over time. Colour 
defect type cannot be used for differential diagnosis of optic neuritis(30). 
4) Visual field 
The field defect in optic neuritis is highly variable with respect to 
size of circumscribed plaques and where the area of complete and 
incomplete demyelination is present. In the optic neuritis treatment trial, 
diffuse field loss was present in 48.2% of eyes, central or centro caecal 
scotomas was present in 8.3% of eyes, altitudinal or other nerve fibre 
bundle type defects were found in 20.1% of eyes and a variety of other 
defects were found in 23.4% of eyes. Bitemporal field defect, contra 
lateral homonymous hemi anopia due to chiasmal or retro chiasmal 
neuritis has been observed in 2.9% of patients. 
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When acuity is severely impaired, perimetric field charting is 
unreliable and confrontation testing is recommended. 
As vision improves, multi isopter kinetic Goldmann perimetry or 
computer assisted automated static perimetry using a Humphrey analyser 
or Octopus perimeter are sensitive techniques for serial testing. 
A finding of generalised depression, para central scotomas or 
scattered nerve fibre bundle – related defects between 5° and 20° from 
fixation, may indicate sequelae of prior demyelinating optic neuropathy. 
5) Optic disc findings 
In acute cases, it may be normal(64%), swollen(23%), blurred or 
hyperaemic(18%) and blurred with peri papillary haemorrhages around 
the disc(2%). Temporal pallor(10%) may be present suggesting previous 
attack in the same eye. 
In recovered optic neuritis, 6 months after the first attack, a normal 
disc can be present in 42% of eyes, temporal pallor in 28% and total disc 
pallor in 18% of eyes. 
In MS in remission, total disc pallor may be present is present in 
38% of cases(31). 
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6) Retina 
Two signs that may be seen in optic neuritis and ms are: 
i) Retinal venous sheathing, resulting from peri phlebitis 
retinae. It is accompanied by vitreous cells. 
ii) Defects in retinal nerve fibre layer. 
Nerve fibre layer defect appears as a slit in associated nerve fibre 
bundles, seen with the use of mono chromic red free ophthalmoscopy 
through dilated pupil. 
Based on fundus finding, optic neuritis is classified into  
i) Retro bulbar neuritis – with normal fundus. 
ii) Papillitis – with disc swelling. 
Special tests 
a) Contrast sensitivity 
Detected by Pelli Robson chart or Regan  letter chart as cycles per 
degree – more sensitive indicator than Snellen’s acuity. 
b) Stereo acuity 
The Titmus Polaroid 3D vectograph stereograph test is 
recommended for both children and adult with optic neuritis. 
The Pulfrich effect in which patients experience a stereo illusion by 
having the patient gaze at a pendulum swinging at right angles to the line 
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of sight and determining if the pendulum appears to the patient to be 
swinging in an elliptical path is a sensitive indicator of optic nerve 
disease. 
c) Visual evoked potential 
It is used to confirm weak evidence of optic neuritis and to 
differentiate organic from functional cause of defective vision. It tests 
central and perifoveal visual field and there is prolongation of P100 
latency(32), which is a permanent change(33). 
Inter ocular difference in P100 latency is also an indicator of optic 
nerve dysfunction; in pattern shift VEP; this has been used to prove optic 
nerve pathology in optic neuritis(34). 
It is a sensitive test, but the specificity is not high, as other 
conditions like glaucoma and compression can also cause increase in 
latency. 
d)  Pattern electro retinogram(PERG) 
PERG monitors integrity of central retinal ganglion cell layer. It is 
of value in improved interpretation of abnormal VEP pattern when both 
are recorded simultaneously, to rule out if delay in pattern VEP P100 
latency in a patient with suspected optic nerve demyelination is not 
caused by more anterior lesions. 
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e) Pupillary light reflex latency(PLRL) 
Prolonged latency of pupillary light reflex which is measured using 
infrared reflection. 
f) Foveal critical flicker frequency 
Subjective brightness measured by Authorn Flicker test in relation 
to flicker frequency is abnormal. 
Features of atypical optic neuritis 
1) Painless 
2) Bilateral 
3) Relatively older patients are affected 
4) Disc h emorrhage & cotton wool spots can occur 
5) Progression of visual loss beyond 2 weeks 
6) Patients fail to improve with treatment 
Investigations 
1) Routine hemogram 
2) Blood culture 
3) ESR 
4) Rule out diabetes 
5) X ray chest 
6) Markers of viral infection 
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7) Serology & culture for bartonella 
8) Syphilis 
9) Hepatitis B 
10) HIV 1 & 2 
11) ANA, dsDNA, RA, ANCA 
12) CSF tap 
13) Visual evoked potential 
14) Giant cell arteritis 
Neuro imaging 
MRI 
a) Enhancing optic nerve on T1 contrast fat saturated- best seen on 
coronal images. On axial images, may have tram-track 
enhancement pattern, simulating optic nerve sheath meningioma. 
b) On T2 with fat saturation (or STIR images) – mildly enlarged 
hyper intense optic nerve. 
c) Acute and chronic MS lesions appear bright in T2 images. Lesions 
are round or ovoid in peri ventricular white matter, internal capsule 
& corpus callosum (perpendicular to venterides, at callososeptal 
interface). They may also be linear with finger like appearance -
Dawson’s fingers. 
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MRI shows the size, quantity and distribution of lesions larger than 
2 mm, and together with supportive evidence, helps in the diagnosis of 
MS(35-37). 
MRI criteria for diagnosing MS 
At least 3 lesions and two of the following should be present for 
the diagnosis to be present(37): 
1) Lesions abutting the lateral ventricles 
2) Lesions with diameters greater than 5 mm 
3) Lesions present in the posterior fossa ( infra tentorial). 
CSF analysis 
ONTT concluded that no patients had their diagnosis or 
management altered as a result of CSF findings. Except for oligo clonal 
bands, few patients showed abnormalities on CSF tests, and no tests 
correlated with the 2-year development of clinically definitive multiple 
sclerosis(CDMS). Thus csf analysis may not be necessary in the routine 
evaluation of patients presenting with a typical clinical profile of acute 
optic neuritis(38). 
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Treatment 
ONTT: Optic Neuritis Treatment Trial 
It was a carefully performed randomized clinical trial and yielded 
useful information. There was no difference in the ultimate visual 
outcome at the 5-year mark in the group treated with steroids when 
compared with the group kept under observation without steroid 
treatment(39-42). 
Study objectives and methods 
1) To evaluate the efficacy of corticosteroid treatment of acute optic 
neuritis. 
2) To investigate the relationship between optic neuritis and multiple 
sclerosis. 
457 patients were divided into 3 treatment groups. 
1) Oral prednisolone(1mg/kg/day) for 14 days 
2) Intra venous methyl prednisolone (1000mg/day) for 3 days, 
followed by oral prednisolone (1mg/kg/day) for 11 days 
3) Oral placebo for 14 days 
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Conclusions 
Fastest recovery was seen in the intra venous group, but at 1-year 
follow up and thereafter, there was no significant difference in the visual 
recovery among the 3 groups. 
Intra venous methyl prednisolone followed by oral prednisolone 
speeds the recovery of visual loss due to optic neuritis and results in 
slightly better vision at 6 months.(39-42) 
 Oral prednisolone alone, as prescribed in this study, is an 
ineffective treatment in the standard doses and increases the risk of new 
episodes of optic neuritis. 
Intra venous steroids followed by oral steroids decrease the 2-year 
incidence of multiple sclerosis. (40) 
Recurrences were more frequent in patients with multiple sclerosis 
and in those treated with oral prednisolone alone.(41) 
Even 10 years after optic neuritis, the neurological impairment was 
mild, with 65% of patients having an Expanded Disability Status Scale 
score lower than 3.0 and the degree of disability appeared to be unrelated 
to whether the baseline MRI scan was lesion-free or showed lesions. (43) 
 Intra venous dexamethasone has been found to be a cheaper and 
effective alternative to methyl prednisolone with less side effects. (44,45) 
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At 1-year follow up, 91%-95% of patients in the 3 groups regained 
acuity of 20/40 or better. Visual prognosis for optic neuritis was generally 
good. At 15 year follow up: 
20/25 or better: 89% 
20/30 to 20/40: 4% 
20/50 to 20/200: 5% 
Worse than 20/200: 2% 
Overall probability of developing clinically definite multiple 
sclerosis at 5 years = 30% 
at 10 years = 38% 
at 15 years = 50% 
MRI findings are strongest predictors of developing clinically 
definite multiple sclerosis at 15 year follow up: 
1) No MRI lesions: 25% 
2) One or more lesions: 72% 
3) Greater number of lesions on MRI increases the likelihood of 
developing multiple sclerosis. 
At 15 year follow up, nerve fibre bundle defects (arcuate, para 
central) were the most common localised visual field abnormalities. 
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Combination of the following substantially decreases the likelihood of 
developing multiple sclerosis(atypical for demyelinating optic neuritis): 
1) Lack of peri ocular pain 
2) Severe optic disc edema 
3) No light perception 
CHAMPS study (The Controlled High Risk Avonex Multiple 
Sclerosis Trial)(46,47): 
It was a prospective, randomized study of 383 patients with first 
acute demyelinating event (optic neuritis, myelitis, brainstem, 
cerebellum) and at least 2 MRI white matter signal abnormalities. 
Study objective: 
This study was undertaken with the objective as to whether 
Interferon beta 1a (Avonex) treatment would benefit patients, who had 
experienced a first acute demyelinating event involving the optic nerve, 
brain stem, cerebellum or spinal cord, and who displayed MRI brain 
abnormalities that have previously predicted a high likelihood of MS-like 
events. 
All patients in this study received intra venous methyl prednisolone 
1g/day for 3 days within 14 days of the onset of their neurological 
symptoms. This was followed by an oral taper beginning with 1mg/kg for 
11 days and ending with a 4 day oral taper. 
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Then patients were divided into 2 groups: 
Group 1: received once weekly intra muscular injection of Interferon beta 
1a(30 micro grams). 
Group 2: received placebo injections. 
Primary outcome measure was development of CDMS and change in 
demyelinating lesions on serial brain MRI scans. 
Results 
1) At the end of 3 years, the probability of CDMS was 50% in the 
placebo treated group & 35% in the Interferon beta 1a treated 
group. 
2) Reduction in the volume of brain lesions in Interferon beta 1a 
group. 
3) Fewer new or enlarging lesions and fewer gadolinium enhancing 
lesions in Interferon beta 1a group. 
4) Trial terminated because of clear benefit of therapy over placebo. 
There was no difference in treatment among patients presenting with 
optic neuritis, brain stem, cerebellar or spinal cord events. 
Treatment with avonex significantly reduced the 2-year likelihood 
of future neurological events & worsening of the brain MRI in patients 
with a first acute CNS demyelinating event.  
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CHAMPIONS study: Controlled High Risk Avonex Multiple 
Sclerosis Prevention Surveillance 
Objective 
This study compared the outcomes in those who had been given 
drug from the start of the CHAMPS study (“immediate treatment” or IT 
group) versus those who had switched from placebo after about 30 
months (“delayed treatment” or DT group). (48)  
It reported that early use of weekly Interferon beta 1a (compared to 
delayed treatment) reduced the likelihood of developing clinically 
definite multiple sclerosis(CDMS) after a 5-year follow up period in 
patients who had initially presented with clinically isolated syndromes 
(CIS) suggestive of MS. 
Results 
Immediate treatment group had significantly fewer relapses and 
fewer brain MRI lesions than the delayed treatment group and that 
significantly fewer of its members converted to definite MS. 
Early Treatment of Multiple Sclerosis (ETOMS) Study Group 
It was a prospective, randomized, multi-centre, double-blind study 
of 300 patients experiencing first episode of neurologic dysfunction 
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suggesting multiple sclerosis within the previous 3 months and strongly 
suggestive brain MRI findings. 
Treatment groups 
1) Interferon beta-1a (Rebif) 22 micro grams subcutaneously once per 
week 
2) Placebo injected subcutaneously once per week 
Results 
1) Fewer patients developed clinically definite multiple sclerosis 
(34%) versus the placebo group (45%; p=0.047) 
2) For 30% of each group to convert to clinically definite multiple 
sclerosis required 569 days in treatment group versus 252 days in 
placebo group (p=0.034) 
3) Annual relapse rate in treatment group was 0.33 versus 0.43 with 
placebo (p=0.045) 
4) Number and total volume of new T2 weighted MRI lesions was 
lower in treatment group 
Betaseron in Newly Emerging Multiple Sclerosis for Initial 
Treatment (BENEFIT) Trial 
Prospective, randomized, multi-centre, double-blind study of 468 
patients experiencing first clinical demyelinating event (mono focal or 
multifocal) & at least 2 brain MRI lesions. 
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Patients were divided into 2 treatment groups 
1) Interferon β-1b (Betaseron) 250 micrograms subcutaneously every 
other day 
2) Placebo injected subcutaneously every other day 
Results: Diagnosis of CDMS established or follow up of 2 years 
1) Reduction of development of CDMS over 2 years from 
45%(placebo) to 28%(treatment) 
2) Similar significant reduction at 2 years if McDonald criteria 
(combines clinical & MRI findings) used: 51%(placebo) versus 
28%(treatment) 
3) At the 25th percentile, time to develop CDMS was delayed from 
255 days(placebo) to 618 days(treatment) 
PreCISe study (early glatiramer acetate treatment in delaying 
conversion to clinically definite multiple sclerosis subjects presenting 
with a clinically isolated syndrome) 
It was a randomized double-blind trial involving 481 patients (80 sites in 
16 countries) presenting with the following: 
1) Clinically isolated syndrome 
2) Two or more T2 brain lesions(≥6mm) 
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Treatment protocol 
1) Glatiramer acetate (Copaxone): 20mg subcutaneous injection per 
day 
2) Placebo – subcutaneous injection 
3) Endpoint: upto 36 months or conversion to CDMS 
Results 
1) Glatiramer acetate reduced the risk of developing CDMS by 45% 
2) Time for 25% of patients to convert to CDMS prolonged from 336 
days to 722 days, if treated with glatiramer acetate 
3) At 5-year follow up, 41% reduced conversion rate to CDMS for 
treated patients. Also, reduction in number of T2 white matter 
lesions and T2 lesion volume 
Although the management of this disorder in adults is well 
described, there is a paucity of evidence-based, prospective clinical data 
on its management & treatment in pediatric population. The current 
treatment of pediatric optic neuritis consists of 3 to 5 days of intra venous 
methyl prednisolone (4-30 mg/kg/day), followed by a prolonged oral 
corticosteroid taper. A prolonged course of oral steroid (2 to 4 weeks) is 
recommended to avoid recurrence, which is common in this age group. 
Some controversy persists concerning the exposure of children to high 
dose parenteral corticosteroids to treat an entity that is usually self-
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limited, but given the severity of vision loss in one or both eyes in this 
population, this intervention is standard in neuro-ophthalmologic 
practice. (49) 
Differential diagnosis 
a) Optic Nerve Compression 
Due to intra cranial masses (eg-pituitary tumours) or orbital masses 
(eg- optic nerve sheath meningioma), papilloedema (bilateral, gradual 
vision loss and disc swelling more than 2 diopters and neurological signs) 
b) Anterior ischemic optic neuropathy 
Visual loss is due to vascular insufficiency because of 
atherosclerotic or inflammatory involvement of posterior ciliary arteries  
Rare before 40 years of age 
No ocular pain on eye movements 
Fundus- pale segmental disc edema, superficial flame shaped 
haemorrhages 
Vision fails to improve in 2 weeks 
Field defects- altitudinal scotoma 
The clinical features may be overlapping, making the diagnosis 
difficult(50). Neural network analysis (an artificial intelligence technique) 
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is a useful technique for classification of optic neuropathies, particularly 
where there is overlap of clinical findings(51). 
c) Toxic or nutritional deficiency amblyopia 
This may be due to exogenous substance (alcohol, tobacco), drugs 
(ethambutol) or nutritional deficiency (pernicious anemia); it presents as 
moderate to marked visual loss, with colour vision deficiency and 
bilateral centro caecal scotoma. 
These are differentiated by being 
1) Painless 
2) Bilateral 
3) Symmetric changes in both eyes 
d) Non organic visual loss 
Hysteria, malingering – classical clinical features are absent. 
e) Leber’s hereditary optic neuropathy 
It is a mitochondrial disease with subacute painless visual loss. It 
affects young males & usually becomes bilateral. Visual recovery is poor. 
f) Other ocular conditions 
1) Posterior uveitis 
2) Central serous retinopathy 
3) Disc drusen 
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4) Glaucoma 
5) Posterior scleritis 
Differentiated by clinical presentation and appearance 
Prognosis 
Though irreversible damage to optic nerve occurs in 85% of optic 
neuritis patients(52), most (60%-80%) regain Snellen’s visual acuity of 6/9 
or better, 45% recover rapidly in first 4 months, 35% recover normal or 
near normal in a year & 20% fail to make any significant improvement. 
Recurrences were more frequent in patients with MS(53). 
Dyschromatopsias, defective stereo acuity, RAPD, delayed 
latencies on VER, defect in contrast sensitivity, Pulfrich & Uhthoff 
phenomenon and persistent field defect may remain as residual defects 
after an attack of optic neuritis. 
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REVIEW OF LITERATURE 
 
In the study by Niphon Chirapapaisan et al,(54) 31 patients (48 eyes) 
were followed up for a mean period of 2.7 years. There were 17 pre-
adolescents (<10 yr age group) in group I & 14 adolescents (10-12 yr 
olds) in group II. Females comprised 59% of group I & 71% of group II. 
Bilateral cases comprised 65% from group I & 43% from group II. Five 
patients from group I had acute disseminated encephalo myelitis(ADEM). 
Two patients from group II had multiple sclerosis.  This study concluded 
that pediatric optic neuritis has no gender or racial predilection, is usually 
bilateral, and is associated with ADEM rather than multiple sclerosis. 
Marco Aurelio Lana-Peixoto et al (55) conducted a study where 
children were divided into 2 groups: group 1 comprised children seen 
upto 2 weeks after the onset of visual loss. Group 2 comprised children 
already having optic atrophy. The mean age was 10.9 years. Optic disc 
pallor was found in 35%, edema in 46% and 19% had normal fundus. 
This study shows that children had a better visual outcome and a lower 
conversion rate to multiple sclerosis than adults. 
In the study by Dong Hyun Jo et al, (56) the mean age at diagnosis 
was 6.5 ± 1.8 years (range 3 to 9 years). 17 patients(85%) were girls & 13 
patients (65%) exhibited bilateral disease. Intra venous corticosteroid 
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treatment was given in 15 patients & exerted a beneficial effect on the 
visual outcomes. Disc swelling was seen in 75.8% of eyes. Multiple 
sclerosis was diagnosed in five patients with a mean follow up period of 
21.9 ± 20.3 months. The presence of lesions in brain MRI images was 
identified as the most significant factor with regards to the occurrence of 
multiple sclerosis. The study confirmed a profound decrease in initial 
visual acuity & rapid recovery of final visual acuity. Cortico steroid 
treatment resulted in a beneficial effect on visual outcomes, but had no 
effect on the risk of multiple sclerosis. 
Michael J. Wan et al (57) made a retrospective study of 59 pediatric 
patients with first episode optic neuritis. The mean age was 12.6 years, 
72% were female, 41% had bilateral involvement, 52% had or developed 
an underlying diagnosis (39% multiple sclerosis, 7% ADEM, 7% neuro 
myelitis optica) & 91% received treatment (85% steroids, 7% 
multimodal). A poor visual outcome at 1 year (<20/40) was associated 
with vision of (<20/20) at 3 months(P= 0.041). other clinical 
characteristics including visual acuity at presentation, sex, bilateral 
involvement, optic nerve edema & underlying diagnoses were not 
significantly associated with poor visual outcomes. 
Michael Absoud et al (58) studied 44 children (female/male ratio 
1.8) median age 10.9 years & were followed up for median 1 year. Optic 
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neuritis was unilateral in 43%. Maximal visual deficit was severe (<6/60) 
in 77% of eyes, with full recovery in 70%. Cumulative probability of 
developing MS (11/44) or NMO (3/44) at 2 yrs was 0.45. relapsing optic 
neuritis was a strong predictor for development of MS or NMO. A 
positive MRI (> 1 brain T2 hyperintense lesion) was a strong predictor 
for development of MS. 
Kathryn M. Brady et al (59) conducted a retrospective analysis of 25 
patient (39 eyes) from 21 months to 18 years of age. 14 patients (56%) 
had bilateral optic neuritis, 11 patients (44%) had unilateral disease. 18 of 
26 affected eyes (50%) recovered vision of 20/40 or better. A normal 
brain MRI was associated with recovery of 20/40 or better visual acuity 
in 6/6 (100%) affected eyes. The study concluded that younger patients 
are more likely to have bilateral disease & a better visual prognosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
PART II 
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AIM 
 To study the clinical characteristics and visual outcome in 
paediatric optic neuritis patients. 
 
OBJECTIVE 
PRIMARY OBJECTIVE 
1) To study the clinical characteristics. 
2) To analyse the visual outcome. 
 
SECONDARY OBJECTIVE 
1) To study the demographic pattern 
2) To study the response to treatment 
3) To follow up for further neurologic sequelae. 
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MATERIALS AND METHODS 
 
TYPE OF STUDY 
Hospital based prospective observational study. 
INCLUSION CRITERIA 
1) Age < 16 years 
2) First episode 
3) No prior neurologic events 
EXCLUSION CRITERIA 
1) Evidence of prior episode. 
2) Uncertainty about the diagnosis. 
3) Compressive lesions, vascular factors. 
4) Confounding factor affecting vision. 
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METHODOLOGY 
Source of data 
All paediatric optic neuritis patients who attended Neuro – 
ophthalmology clinic, Aravind Eye Hospital and Post Graduate Institute 
of Ophthalmology, Madurai. 
Period of study 
The period of study was from May 2016 to April 2017. Patients 
were recruited for the period of 1 year and subsequently each case was 
followed up for 3 months. 
• A detailed history was obtained from each patient which included 
 Ocular complaints 
 Systemic symptoms 
• A complete ocular examination was performed at each visit which 
included 
 Best corrected visual acuity using Snellens’ chart 
 Pupils 
 EOM 
 Colour vision, fields, brightness sensitivity, red saturation 
 Fundus examination with 90 D lens 
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• A data form was prepared which collected information on 
 Demographic data including age at presentation, gender 
 Extra ocular neurological symptoms 
• Ophthalmic data recorded which included 
 Age at onset 
 Laterality 
 Visual acuity 
 Ocular findings 
 Ocular complications 
 Investigation (if needed) 
Imaging – MRI brain with contrast 
         CT brain 
         Chest X ray 
Blood investigations – Hb, TC, DC, ESR,  Blood urea, Serum creatinine. 
Mantoux test 
• The treatment advised for each patient was documented. 
• The patient was examined on each follow up visit (1 month, 3 
months) 
• Collected data was statistically analysed. 
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STATISTICAL TESTS USED 
1. Proportion 
2. Mean 
3. McNemar’s test 
p value less than 0.05 was considered as statistically significant. 
DATA ENTRY AND ANALYSIS 
Microsoft excel and STATA 11 (TEXAS USA) were used. 
ETHICAL CONSIDERATION 
 The protocol designed for the present study was submitted to the 
Ethical committee, Aravind Eye Hospital and Post Graduate Institute of 
Ophthalmology, Madurai. After getting clearance from the Research 
Committee, Ethical clearance certificate was issued by the institution. 
Consent was also taken and Confidentiality of the data was maintained. 
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RESULTS 
 
This study included a total of 54 eyes of 38 paediatric patients and 
was conducted at the Neuro-ophthalmology clinic of Aravind Eye 
Hospital and Post Graduate Institute of Ophthalmology, Madurai in the 
period of May 2016 to April 2017. 
DEMOGRAPHIC PATTERN IN PAEDIATRIC OPTIC NEURITIS 
PATIENTS 
AGE AT PRESENTATION 
The mean age at presentation in the present study was 10.6 years. 
The youngest patient was 5 years old and the oldest patient was 14 years 
old.  
AGE BASED DISTRIBUTION OF CASES 
Of the 38 patients, 18(47.36%) patients were less than 10 years of 
age (group I) & 20(52.63%) patients were above 10 years of age (group 
II). In group I, there were 9 boys (50%) and 9 girls (50%). In group II, 
there were 7 boys (35%) and 13 girls (65%). 
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Age (in years) 
No. of patients 
(Percentage) 
No. of girls No. of boys 
<10 years  
(group I) 
18 (47.36) 9 9 
>10 years  
(group II) 
20 (52.63) 13 7 
Total 38 22 16 
 
 
 Group I Group II 
 Number (Percentage) Number (Percentage) 
Girls 9 (50) 13 (65) 
Boys 9 (50) 7 (35) 
Total 18 (100) 20 (100) 
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GENDER 
Of the 38 patients, 22(58%) were girls and 16(42%) were boys. Of 
the 22 girls, 9 (40.9%) belonged to group I and 13 (59.1%) belonged to 
group II. Of the 16 boys, 9 (56.2%) belonged to group I and 7 (43.7%) 
belonged to group II. 
 
 
 Girls Boys 
 Number (Percentage) Number (Percentage) 
Group I 9 (40.9) 9 (56.2) 
Group II 13 (59.1) 7 (43.7) 
Total 22 (100) 16 (100) 
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44 
 
LATERALITY 
Of the 38 patients, Optic neuritis was found to be unilateral in 22 
patients (58%) and bilateral in 16 patients (42%). In group I, unilateral 
disease was seen in 9 (50%) patients and bilateral disease was seen in 9 
(50%) patients.  
In group II, unilateral disease was seen in 13 (65%) patients and 
bilateral disease was seen in 7 (35%) patients, of which 1 patient had 
bilateral sequential disease, with the second eye being affected 1 month 
after the involvement of the first eye. 
 
 
 
 Group I Group II 
 Number (Percentage) Number (Percentage)
Unilateral 9 (50) 13 (65) 
Bilateral 9 (50) 7 (35) 
Total 18 (100) 20 (100) 
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PAIN 
Pain during eye movements was present in 10(26%) of the patients, 
while there was no pain during presentation in 28(74%) of the patients. 
Pain present 10(26%) 
Pain absent 28(74%) 
Total 38 (100%) 
 
HEADACHE 
Headache was absent in 21(55%) of patients, while it was present 
in 17(45%) of patients at presentation. 
Headache present 17(45%) 
Headache absent 21(55%) 
Total 38 (100%) 
 
FEVER 
Fever was present in 12(31%) of the patients during presentation, 
while 26(68%) patients had no fever at or before presentation. 
Fever present 12(31%) 
Fever absent 26(68%) 
Total 38 (100%) 
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PUPIL 
Pupils were normal in 2 (3.7%) of 54 eyes, ill sustained in 27 eyes 
(50%) and showed RAPD in 25 eyes (46.29%). In 2 patients with 
bilateral optic neuritis, the disease was asymmetric in BE, thus one eye 
had RAPD and the other eye showed ill sustained reaction to light. 1 
patient had bilateral sequential disease. At presentation, 1 eye was 
involved and so, it showed RAPD. After 1 month, the other eye also 
developed optic neuritis. 
 
Pupil No. of eyes Percentage 
Normal 2 3.7 
Ill sustained 27 50 
RAPD 25 46.29 
Total 54 100 
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DEFECTIVE VISION 
At presentation, visual acuity was normal (6/6) in 2 (3.7%) of 54 
eyes. 3 (5.55%) eyes had vision in the range of 6/9 - 6/18. 5 (9.25%) eyes 
had vision in the range of 6/24 – 6/36. 44 (81.48%) of 54 eyes had severe 
visual deficit - <6/60, of which 2 eyes (3.7%) had no light perception. 
 
Visual acuity Number of eyes Percentage 
6/6 2 3.7 
6/9 – 6/18 3 5.55 
6/24 – 6/36 5 9.25 
6/60 – 1/60 26 48.14 
FCF – PL 16 29.62 
No PL 2 3.7 
total 54 100 
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DYSCHROMATOPSIA 
At presentation, colour vision was normal in 2 (3.7%) of 54 eyes, 
defective in 17 of 54 eyes (31.4%). Colour vision could not be elicited 
due to poor vision in 31 (57.4%) of 54 eyes. 1 patient had no light 
perception in BE. 1 patient (BE) was not co-operative for colour vision 
examination. 
 
Colour vision Number of eyes Percentage 
Normal 2 3.7 
Defective 17 31.4 
Poor vision 31 57.4 
Not co-operative 2 3.7 
No light perception 2 3.7 
Total 54 100 
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FIELD DEFECTS 
Of the 54 eyes of 38 patients, 32 eyes (59.2%) had very poor vision 
to examine for field defects. 2 eyes (3.7%) had no field defects. There 
was no light perception in 2 eyes. Generalised constriction of visual fields 
was seen in 6 eyes (11.1%), while centro caecal scotoma was seen in 4 
eyes (7.4%). The remaining patients were not co-operative for visual 
fields examination. 
 
Visual fields Number of eyes Percentage 
Normal 2 3.7 
Centro caecal scotoma 4 7.4 
Generalised 
constriction 6 11.1 
Poor vision 32 59.2 
Not co-operative 8 14.8 
No light perception 2 3.7 
Total 54 100 
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BRIGHTNESS SENSITIVITY 
At presentation, brightness sensitivity was normal in 2 (3.7%) of 
54 eyes and reduced in 37 eyes (68.5%). Vision was too poor to examine 
in 11 eyes (20.4%) and 1 patient had no light perception in BE. 1 patient 
(BE) was not co-operative for examination. 
 
 
Brightness sensitivity Number of eyes Percentage 
Normal 2 3.7 
Reduced 37 68.5 
Poor vision 11 20.4 
Not co-operative 2 3.7 
No light perception 2 3.7 
Total 54 100 
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RED DESATURATION 
It was normal in 2 (3.7%) of 54 eyes and reduced in 12 eyes 
(22.2%) at presentation. Vision was too poor to examine in 36 eyes 
(66.7%) and 1 patient had no light perception in BE. 1 patient (BE) was 
not co-operative for examination. 
 
Red desaturation Number of eyes Percentage 
Normal 2 3.7 
Reduced 12 22.2 
Poor vision 36 66.7 
Not co-operative 2 3.7 
No light perception 2 3.7 
Total 54 100 
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FUNDUS 
At presentation, disc appeared normal in 8 (14.8%) of 54 eyes. 
Edema was present in 42 eyes (77.7%). Disc was hyperemic in 2 eyes 
(3.7%). Temporal pallor was present in both the eyes (3.7%) of a patient 
who presented to us after 15 days of the onset of symptoms. 
 
Fundus Number of eyes Percentage 
Edema 42 77.7 
Hyperemia 2 3.7 
Normal 8 14.8 
Temporal pallor 2 3.7 
Total 54 100 
 
 
 
 
 
 
 
59 
 
 
 
 
 
 
 
 
  
8 
42 
2 2 
Normal Edema Hyperemia Temporal pallor
Fundus appearance 
60 
 
IMAGING 
MRI was not done in all patients due to financial constraints. MRI 
was done in 22 cases and CT was done in 16 cases. Imaging was normal 
in 15 cases. Demyelinating lesions were present in the brain in 4 cases, 
suggestive of multiple sclerosis. 1 patient had TB optico chiasmatic 
arachnoiditis. 1 patient had meningitis with RBN. 1 patient had features 
suggestive of Superior Orbital Fissure syndrome/ Orbital Apex 
Syndrome. The remaining 16 patients had thickening and enhancement of 
optic nerve in the affected eye. 
 
TREATMENT 
All patients with idiopathic optic neuritis or demyelinating lesions 
on imaging (suggestive of multiple sclerosis) were treated initially with 
intra venous methyl prednisolone (15 to 30 mg/kg/day) OD for 3 to 5 
days. This was followed by a course of oral steroids – 1mg/kg/day for 11 
days, followed by gradual taper. The patient with TB optico chiasmatic 
arachnoiditis was treated with Anti Tuberculosis Therapy.  
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FOLLOW UP 
1) VISION 
At 1 month follow up, 11 eyes (20.37%) had 6/6 when compared to 
2 eyes (3.7%) at presentation. 11 eyes had 6/12, 17 eyes had 6/9, 4 eyes 
had 6/18 and 4 eyes had 6/36 vision. 3 eyes (5.55%) had vision in the 
range of 6/60 – 1/60. 4 eyes (7.4%) had HM: 1 patient (BE) with TB 
optico chiasmatic arachnoiditis and another patient (BE) with possible 
RBN. 
At 3 months follow up, 31 eyes (57.4%) recovered 6/6 vision. 17 
eyes (31.48%) had 6/9. 1 patient with meningitis and RBN had 6/60 
vision in 1 eye and 6/36 vision in the other eye. 1 patient with TB optico 
chiasmatic arachnoiditis had FCF in 1 eye and HM in the other eye. 1 
patient with possible RBN had HM in BE at 3 months follow up. 
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Visual acuity At presentation 1 month 3 months 
 No. of eyes (Percentage) 
No. of eyes 
(Percentage) 
No. of eyes 
(Percentage) 
6/6 2 (3.7) 11 (20.37) 31 (57.4) 
6/9 – 6/18 3 (5.55) 32 (59.25) 17 (31.48) 
6/24 – 6/36 5 (9.25) 4 (7.4) 1 (1.85) 
6/60 – 1/60 26 (48.14) 3 (5.55) 1 (1.85) 
FCF – PL 16 (29.62) 4 (7.4) 4 (7.4) 
No PL 2 (3.7) - - 
Total 54 (100) 54 (100) 54 (100) 
 
Mc Nemar’s test was used to determine the difference between pre 
and post treatment binary data in the case of visual acuity. The test 
yielded a p value of 0.0000002 which is statistically significant. Thus it 
can be concluded that there is significant improvement in visual acuity of 
the test candidates after treatment at 3rd month follow up. 
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2) COLOUR VISION 
38 of 54 eyes (70.37%) had regained good colour vision at 1 month 
follow up. 1 patient (BE) was not co-operative for colour vision 
examination. In 5 eyes (9.25%) of 3 patients, vision was too poor to 
examine colour vision- 1 patient (BE) had TB optico chiasmatic 
arachnoiditis, 1 patient (BE) had possible RBN and another patient had 
meningitis with RBN. 
In the remaining eyes, colour vision was defective at 1 month 
follow up. 
At 3 months follow up, 43 eyes (79.62%) had regained good colour 
vision. 1 patient with MS read 13/21 plates. Another patient with MS 
(BE) read 2/21 plates. 1 patient (BE) with meningitis and RBN read 1/21 
plates.  
Vision was too poor to examine colour vision in 1 patient (BE) 
with TB optico chiasmatic arachnoidits and another patient (BE) with 
possible RBN. 1 patient (BE) was not co-operative for examination. 
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Colour vision At presentation 1 month 3 months 
 No. of eyes (Percentage) 
No. of eyes 
(Percentage) 
No. of eyes 
(Percentage) 
Defective 17 (31.4) 9 (16.65) 5 (9.25) 
Good 2 (3.7) 38 (70.37) 43 (79.62) 
Poor vision 31 (57.4) 5 (9.25) 4 (7.4) 
Not co-
operative 2 (3.7) 2 (3.7) 2 (3.7) 
No light 
perception 2 (3.7) - - 
Total 54 (100) 54 (100) 54 (100) 
 
 
p value (Mc Nemar’s test) showed difference between pre and post 
treatment binary data in the case of colour vision to be 0.000000, which is 
statistically significant. Thus, it is proved that there is significant 
improvement in colour vision of patients after treatment, at 3rd month 
follow up. 
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RECOVERY OF VISION & COLOUR VISION 
No laterality 
BCVA-
present
ation 
CV imaging 
BCVA
-1 
month 
CV-1 
month 
BCVA
-
3mont
hs 
CV-3 
months 
Treat
ment 
1 BE HM Poor vision 
Thickened optic 
nerves 6/9. 19/21 6/6. 21/21 
I.V 
MP 
  HM 
Poor 
vision  6/9. 19/21 6/6. 21/21  
2 BE 1/2 /60. Poor vision 
Thickened optic 
nerves. Possible 
RBN 
6/6. 20/21 6/6. 21/21 I.V MP 
  1/2 /60. 
Poor 
vision  6/6. 20/21 6/6. 21/21  
3 RE 6/18. Defective Possible RBN 6/9. 20/21 6/6. 21/21 I.V MP 
4 LE 1/60. Defective Thickened optic nerves 6/9. 20/21 6/6. 21/21 
I.V 
MP 
5 BE 3/60. Poor vision Normal 6/6. 21/21 6/6. 21/21 
I.V 
MP 
  HM 
Poor 
vision  6/9p. 5/21. 6/6p 19/21  
6 LE 6/18. Defective Normal 6/9. 19/21 6/9. 21/21 I.V MP 
7 RE HM Poor vision 
Possible RBN/ 
CIS 6/6p. 21/21 6/6. 21/21 
I.V 
MP 
8 BE PL Poor vision MS 5/60. 1/21. 6/9p 2/21. 
I.V 
MP 
  FCF 
Poor 
vision  6/36. 1/21. 6/6p 2/21.  
9 RE 1/60. Poor vision Normal 6/9. 19/21 6/6p 21/21 
I.V 
MP 
10 BE 3/60. Defective Normal 6/12. 20/21 6/6p 20/21 I.V MP 
3/60. Defective 6/6p. 21/21 6/6. 21/21 
11 LE HM Poor vision MS 6/9. 11/21. 6/9. 13/21 
I.V 
MP 
12 BE RE No PL No vision 
TB - optico 
chiasmatic 
archnoiditis 
HM Poor vision FCF 
Poor 
vision ATT 
  
LE No 
PL No vision  HM 
Poor 
vision HM 
Poor 
vision  
13 BE 6/6p 21/21 Possible RBN 6/6. 21/21 6/6. 21/21 I.V MP 
2/60. 0/21 6/6. 21/21 6/6. 21/21 
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14 BE 1/60. Poor vision Possible RBN HM 
Poor 
vision HM 
Poor 
vision 
I.V 
MP 
  1/60. 
Poor 
vision  HM 
Poor 
vision HM 
Poor 
vision  
15 BE 6/36. 1/21. ? MS 6/9. 19/21 6/6. 20/21 I.V MP 
6/36. 1/21. 6/9. 19/21 6/6. 20/21 
16 BE 4/60. 0/21. Possible RBN 6/12. 17/21 6/6. 20/21 I.V MP 
4/60. 0/21. 6/12. 17/21 6/6. 20/21 
17 RE PL Poor vision Normal 6/36. 19/21 6/9. 21/21 
I.V 
MP 
18 RE PL Poor vision 
? SOF/ ?Orbital 
apex syndrome 6/18. 11/21. 6/9. 20/21. 
I.V 
MP 
19 BE 5/60. 1/21. RBN 6/6. 20/21 6/6. 21/21 I.V MP 
  PL 
Poor 
vision  6/12. 17/21 6/6p 21/21  
20 BE Fix light not co operative 
Thickened optic 
nerves 6/9p. 
not co 
operati
ve 
6/9. not co operative
I.V 
MP 
  Fix light 
not co 
operative  6/6. 
not co 
operati
ve 
6/6. not co operative  
21 BE 1/60. Poor vision RBN 6/12. 19/21 6/6p 20/21 
I.V 
MP 
  3/60. 
Poor 
vision  6/9. 20/21 6/6. 21/21  
22 BE 1/60. Poor vision possible RBN 6/6. 21/21 6/6. 21/21 
I.V 
MP 
  1/60. 
Poor 
vision  6/6p. 20/21 6/6p 21/21  
23 BE FCF Poor vision 
Meningitis with 
RBN 3/60. 
Poor 
vision 6/60. 1/21. 
I.V 
MP 
  5/60. 
Poor 
vision  6/36. 1/21. 6/36. 1/21.  
24 RE 1/60. Poor vision Normal 6/9. 21/21 6/6. 21/21 
I.V 
MP 
LE 6/6. 21/21 2/60. 0/21 6/9. 20/21 
25 RE 1/60. Poor vision Normal 6/18. 20/21 6/9. 21/21 
I.V 
MP 
26 RE 6/36. Defective RBN 6/9. 20/21 6/6. 21/21 I.V MP 
27 RE 6/36. Defective Normal 6/9. 20/21 6/6p 21/21 I.V MP 
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28 RE 1/60. Poor vision Normal 6/12. 19/21 6/9. 21/21 
I.V 
MP 
29 RE 6/24. Defective Thickened optic nerves 6/9p. 20/21 6/9. 21/21 
I.V 
MP 
30 LE 1/60. Poor vision Normal 6/18. 13/21 6/9. 21/21 
I.V 
MP 
31 LE PL Poor vision Normal 6/36. 9/21. 6/9p 19/21 
I.V 
MP 
32 LE 6/12. Defective Normal 6/9. 20/21 6/9. 21/21 I.V MP 
33 LE 4/60. Defective Thickened optic nerve 6/12. 19/21 6/9. 21/21 
I.V 
MP 
34 RE 1/60. Poor vision 
Thickened optic 
nerve 6/12. 20/21 6/6p 21/21 
I.V 
MP 
35 RE 1/60. Poor vision Normal 6/18. 19/21 6/9. 21/21 
I.V 
MP 
36 RE 3/60. Poor vision 
Thickened optic 
nerve 6/12p 18/21 6/9. 21/21 
I.V 
MP 
37 RE 4/60. Defective Normal 6/12p 18/21 6/6p. 21/21 I.V MP 
38 LE 1/60. Poor vision Normal 6/12. 16/21 6/9. 21/21 
I.V 
MP 
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3) FIELDS 
At 1 month follow up, field of vision was normal in 45 (83.3%) of 
54 eyes when compared to 2 eyes (3.7%) at presentation. 1 patient (BE) 
was not co-operative for examination.  
Field defects were present in 2 eyes. Vision was too poor for 
examination in 5 eyes (9.25%) of 3 patients – 1 patient (BE) with TB 
optico chiasmatic arachnoiditis, 1 patient (BE) with possible RBN and in 
1 eye of a patient with bilateral subsequent optic neuritis. 
At 3 months follow up, fields were normal in 46 eyes (85.18%). 1 
patient (BE) was not co-operative for examination. 1 patient (BE) (3.7%) 
with meningitis and RBN had residual field defects.  
Vision was too poor for examination in 4 eyes (7.4%) of 2 patients 
– 1 patient (BE) with TB optico chiasmatic arachnoiditis and another 
patient (BE) with possible RBN. 
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Visual fields At presentation 1 month 3 months 
 No. of eyes (Percentage) 
No. of eyes 
(Percentage) 
No. of eyes 
(Percentage) 
Normal 2 (3.7) 45 (83.3) 46 (85.18) 
Defective 10 (18.51) 2 (3.7) 2 (3.7) 
Poor vision 32 (59.25) 5 (9.25) 4 (7.4) 
Not co-
operative 8 (14.8) 2 (3.7) 2 (3.7) 
No light 
perception 2 (3.7) - - 
Total 54 (100) 54 (100) 54 (100) 
 
 
 
2 
45 46 
10 
2 2 
32 
5 4 
8 
2 2 2 
Presentation 1 month 3 months
Fields at presentation & follow up 
Normal Defective Poor vision Not co-operative No light perception
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4) BRIGHTNESS SENSITIVITY 
At 1 month follow up, 19 (35.2%) of 54 eyes had normal 
brightness sensitivity when compared to 2 eyes (3.7%) at presentation. It 
was reduced in 29 eyes (53.7%) and vision was very poor for 
examination in 4 eyes (7.4%). 1 patient (BE) was not co-operative for 
examination. 
At 3 months follow up, brightness sensitivity was normal in 33 
eyes (61.1%) and reduced in 15 eyes (27.8%). Vision was poor for 
examination in 4 eyes (7.4%) of 2 patients – 1 patient (BE) with TB 
optico chiasmatic arachnoiditis and another patient (BE) with possible 
RBN. 1 patient (BE) was not co-operative for examination. 
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Brightness 
sensitivity At presentation 1 month 3 months 
 No. of eyes (Percentage) 
No. of eyes 
(Percentage) 
No. of eyes 
(Percentage) 
Normal 2 (3.7) 19 (35.2) 33 (61.1) 
Reduced 37 (68.5) 29 (53.7) 15 (27.8) 
Poor vision 11 (20.4) 4 (7.4) 4 (7.4) 
Not co-
operative 2 (3.7) 2 (3.7) 2 (3.7) 
No light 
perception 2 (3.7) - - 
Total 54 (100) 54 (100) 54 (100) 
 
 
 
 
2 
19 
33 
37 
29 
15 
11 
4 4 2 2 2 2 
Presentation 1 month 3 months
Brightness sensitivity at presentation & 
follow up 
Normal Reduced Poor vision Not co-operative No light perception
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5) RED DESATURATION 
At 1 month, red desaturation was normal in 6 (11.1%) of 54 eyes, 
when compared to 2 eyes (3.7%) at presentation. It was reduced in 40 
eyes (74%) and vision was too poor for examination in 6 eyes (11.1%). 1 
patient (BE) was not co-operative for examination. 
At 3 months follow up, red desaturation was normal in 16 eyes 
(29.6%) and reduced in 32 eyes (59.3%). Vision was too poor for 
examination in 4 eyes (7.4%) of 2 patients- 1 patient (BE) with TB optico 
chiasmatic arachnoiditis and another patient (BE) with possible RBN. 1 
patient (BE) was not co-operative for examination. 
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Red 
desaturation At presentation 1 month 3 months 
 No. of eyes (Percentage) 
No. of eyes 
(Percentage) 
No. of eyes 
(Percentage) 
Normal 2 (3.7) 6 (11.1) 16 (29.6) 
Reduced 12 (22.2) 40 (74) 32 (59.3) 
Poor vision 36 (66.7) 6 (11.1) 4 (7.4) 
Not co-operative 2 (3.7) 2 (3.7) 2 (3.7) 
No light 
perception 2 (3.7) - - 
Total 54 (100) 54 (100) 54 (100) 
 
 
 
 
2 
6 
16 
12 
40 
32 
36 
6 4 2 2 2 2 
Presentation 1 month 3 months
Red desaturation at presentation & follow 
up 
Normal Reduced Poor vision Not co-operative No light perception
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6) FUNDUS 
At 1 month follow up, disc appeared normal in 8 (14.8%) of 54 
eyes. Disc edema was present in 1 eye (1.85%) (This had bilateral 
sequential optic neuritis).  
Resolving disc edema was seen in 1 eye (1.85%). Temporal pallor 
was seen in 40 eyes (74%). Disc pallor was seen in 4 eyes (7.4%) of 3 
patients- 1 patient (BE) with TB optico chiasmatic arachnoiditis, 1 patient 
with meningitis and RBN and 1 patient with thickened optic nerves on 
imaging. 
At 3 months, disc appeared normal in 8 eyes (14.8%). Temporal 
pallor was seen in 42 eyes (77.7%). Disc pallor was seen in 4 eyes (7.4%) 
of the 3 patients, as in the previous visit. 
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Fundus At presentation 1 month 3 months 
 No. of eyes (Percentage) 
No. of eyes 
(Percentage) 
No. of eyes 
(Percentage) 
Edema 42 (77.7) 1 (1.85) - 
Hyperemia 2 (3.7) - - 
Resolving disc 
edema - 1 (1.85) - 
Normal 8 (14.8) 8 (14.8) 8 (14.8) 
Temporal pallor 2 (3.7) 40 (74) 42 (77.7) 
Disc pallor - 4 (7.4) 4 (7.4) 
Total 54 (100) 54 (100) 54 (100) 
 
 
 
42 
1 2 1 
8 8 8 
2 
40 42 
4 4 
Presentation 1 month 3 months
Fundus appearance at presentation & follow 
up 
Edema Hyperemia Resolving disc edema Normal Temporal pallor Disc pallor
78 
 
DISCUSSION 
 
The mean age at presentation in the present study was 10.6 years. 
Marco Aurelio Lana – Peixoto et al (55) reported a mean age of 10.9 years. 
Dong Hyun Jo et al (56) reported a mean age at diagnosis to be 6.5 +/- 1.8 
years (range 3 to 9 years). 
In the study by Michael J. Wan et al, (57) the mean age was 12.6 
years. In the study by Michael Absoud, (58) the median age was 10.9 
years.  
Present study correlates with the general mean age of presentation 
of paediatric optic neuritis patients all over the world. 
 
In the present study, the disease was found to be unilateral in 22 
patients (58%) and bilateral in 16 patients (42%), of which 1 patient had 
bilateral sequential disease, with 1 eye being affected 1 month after the 
involvement of the first eye. 
Dong Hyun Jo et al (56) reported bilaterality in 65% of the patients. 
Michael J. Wan et al (57) reported bilateral disease in 41% of the 
patients. 
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Michael Absoud et al (58) found the disease to be unilateral in 43% 
of the patients. 
Kathryn M. Brady et al (59) reported the disease to be unilateral in 44% of 
the patients. 
In terms of laterality, our study was comparable to the other 
studies. 
 
In the present study, in group I (<10 years of age), 9 (50%) patients 
had unilateral disease and 9 (50%) patients had bilateral disease. In group 
II (>10 years of age), 13 (65%) patients had unilateral disease, while 7 
(35%) patients had bilateral disease. 
In the study by Niphon Chirapapaisan et al, (54) bilateral cases 
comprised 65% from group I and 43% from group II, which is 
comparable to the distribution of cases in the present study. 
 
In the present study, of the 38 patients, 22(58%) were girls and 
16(42%) were boys. 
Michael J. Wan et al (57) reported that 72% of the patients were 
females in their study. 
In the study by Dong Hyun Jo et al, (56) 17(85%) patients were 
girls. 
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Michael Absoud et al (58) reported female/ male ratio to be 1.8. 
In the present study, incidence of the disease is higher among girls, 
like in the other studies. 
In the present study, girls comprised 50% (9 patients) of group I 
(<10 years) and 65% (13 patients) of group II (> 10 years). 
 In the study by Niphon Chirapapaisan et al, (54) females comprised 
59% of group I (< 10 years) and 71% of group II (10-12 years). 
 This shows that incidence of the disease is higher among girls, 
especially in group II (> 10 years of age). 
 
In the present study, at presentation, 44 of 54 (81.48%) eyes had 
vision <6/60, of which 2 eyes (3.7%) had no light perception. 
At 3 months follow up, full recovery (6/6) was seen in 31 (57.4%) 
o f 54 eyes. 48 of 54 (88.9%) eyes recovered vision of >6/18.  Vision was 
<6/60 in 5 (9%) eyes. 
Michael Absoud et al (58) reported severe visual deficit (<6/60) in 
77% of eyes, with full recovery in 70%. 
Kathryn M. Brady et al (59) reported that 18 of 26 (50%) affected 
eyes recovered vision of 20/40 or better. 
When compared to other studies, the present study also 
demonstrated a very good visual recovery in the paediatric patients. 
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In the present study, 2 eyes (3.7%) had normal colour vision at 
presentation, while 43 eyes (79.6%) recovered normal colour vision at 3 
months 
In the present study, visual fields were normal in 2 eyes (3.7%) at 
presentation, while 46 eyes (85.18%) recovered normal visual fields at 3 
months. 
In the present study, brightness sensitivity was normal at 
presentation in 2 (3.7%) of 54 eyes and reduced in 37 (68.5%) of 54 eyes. 
At 3 months follow up, brightness sensitivity had recovered to normal in 
33 (61.1%) of 54 eyes and reduced in 15 (27.8%) of 54 eyes.  
In the present study, red desaturation was normal at presentation in 
2 (3.7%) of 54 eyes and reduced in 12 (22.2%) of 54 eyes. At 3 months 
follow up, red desaturation recovered to normal in 16 (29.6%) of 54 eyes 
and reduced in 32 (59.2%) of 54 eyes.  
At 3 months follow up, even though colour vision had recovered to 
normal in 43 (79.6%) of 54 eyes, red desaturation had recovered to 
normal in only 16 (29.6%) of 54 eyes, showing that the quality of colour 
vision was suboptimal in the recovered eyes. All the other parameters like 
visual acuity, colour vision, visual fields, brightness sensitivity had 
recovered by 3 months, except for red desaturation. This shows that red 
desaturation is a very sensitive indicator of prior optic nerve damage, 
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being left behind as the footprint of the disease, while all other 
parameters recovered back to normal. 
In the present study, fundus was normal in 8 (14.8%) of 54 eyes. 
Disc edema was present in 42 (77.77%) of 54 eyes, hyperemia was 
present in 2 (3.7%) of 54 eyes and temporal pallor was present in 2 
(3.7%) of 54 eyes at presentation. 
Marco Aurelio Lana – Peixoto et al (55) reported optic disc pallor in 
35%, edema in 46% and normal fundus in 19%. 
Dong Hyun Jo et al (56) reported disc swelling in 75.8% of the eyes. 
This shows that disc edema is more common in paediatric optic 
neuritis patients and is comparable with other studies. 
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LIMITATIONS 
In our study, the follow up period was very short. Paediatric optic 
neuritis is a recurrent entity, which needs long term follow up, to look for 
neurologic sequelae. 
CT was done in some patients in our study, due to financial 
constraints. MRI with contrast is a sensitive tool to pick up CNS 
demyelinating lesions, suggestive of multiple sclerosis.  
CSF analysis & HLA typing was not done in our patients. 
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SUMMARY 
The mean age of presentation in our study was 10.6 years. 
There were 18 patients (47.36%) in group I (< 10 years of age) and 
20 patients (52.63%) in group II (> 10 years of age). 
The disease was unilateral in 22 patients (58%) and bilateral in 16 
patients (42%). 
The incidence was higher among girls (22 girls – 58%) when 
compared to boys (16 boys – 42%). In group I, the incidence was equal 
among boys (50%) and girls (50%). In group II, the incidence was higher 
in girls (65%) when compared to boys (35%). This reflects the emergence 
of adult pattern of disease distribution in patients more than 10 years of 
age. 
Vision loss in paediatric optic neuritis patients is profound at 
presentation. 81.48% of eyes had severe visual loss (<6/60) in our study, 
of which 2 eyes had no perception of light. 
Disc edema is seen in 77.77% of eyes at presentation. 
At 3 months follow up, visual acuity recovered to normal (6/6) in 
31 eyes (57.4%), with 48 eyes (88.9%) recovering visual acuity > 6/18. 
This shows that paediatric optic neuritis patients have excellent visual 
recovery. 
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At 3 months follow up, visual acuity, colour vision, visual fields 
and brightness sensitivity had recovered well in majority of the patients. 
Red desaturation had recovered to normal in only 29.6% of eyes at 
3 months follow up, even though colour vision had recovered to normal 
in 79.6% of eyes, showing that the quality of colour vision was poor in 
the recovered eyes, when compared with normal eyes. 
Imaging showed demyelinating lesions in 4 patients (10.5%), 
indicating that it is rare in children when compared with adults. 
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CONCLUSION 
 
Paediatric optic neuritis patients have profound loss of vision at 
presentation, when compared with their adult counterparts. They have 
excellent visual recovery following treatment, though serious visual 
disability does occur in few patients. Optic neuritis in children may be the 
initial manifestation of demyelinating diseases like multiple sclerosis. So, 
the clinicians should be aware of the neurologic sequelae while treating 
paediatric optic neuritis patients. 
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CLINICAL PHOTOS 
 
Figure 1 Papillitis 
 
Figure 2 Neuro retinitis 
 Figure 3 Optic atrophy 
 
 
  
Figure 4 Temporal pallor 
 
  
CLINICAL FEATURES AND VISUAL OUTCOME IN 
PAEDIATRIC OPTIC NEURITIS 
PROFORMA 
 
MR no:    Age:   Study no: 
Name:       Gender: 
Address:       Contact no: 
Complaints: 
1) Defective vision – Onset 
Duration 
Progressive/ stationary 
Unilateral or bilateral 
Painless or painful 
2) Colour vision defect     - Yes / No 
3) Field defect       - Yes / No 
4) Eye pain-worsening on eye movements                - Yes / No 
5) Headache                - Yes / No 
6) Redness       - Yes / No 
7) Fever        - Yes / No 
8) Vaccination       - Yes / No 
9) Lhermitte sign      - Yes / No 
    10)Cough, URI          - Yes / No 
    11)Myalgia, joint pain        - Yes / No 
    12)Weight loss         - Yes / No 
    13)Trauma        - Yes / No 
    14)Tuberculosis        - Yes / No 
    15)Others 
 
Diet history:  Veg / Non veg 
General exam: 
Built:     Pallor: 
Pulse:     BP: 
CVS:     RS:    CNS: 
Ocular exam:   RE    LE 
UCVA 
BCVA 
Anterior segment       
Pupil- Normal 
  Sluggish 
 RAPD 
EOM- Full / Restricted 
   Painful / Painless    
  
         
Colour vision-   Normal / Defective 
Central fields- 
 Normal 
 Central scotoma 
 Centro caecal scotoma 
 Altitudinal field defect 
 Generalised contraction 
 Enlargement of blind spot 
Brightness sensitivity- Normal / Reduced 
Red desaturation- Normal / Reduced 
Fundus –         
Normal 
Edema 
Hyperemia 
Temporal pallor 
Macula- 
Investigations: 
MRI with contrast 
CT brain 
 Chest X ray 
 
 
Blood investigations- TC 
DC 
ESR 
Hb 
Blood urea 
Serum creatinine 
Mantoux 
 
Treatment 
 
 
Follow up: 1 month 
Subjective improvement: Yes / No 
Ocular exam:      RE  LE 
UCVA 
BCVA 
Anterior segment-       
Pupil- Normal 
  Sluggish 
           RAPD 
          
EOM- Full / Restricted 
   Painful / Painless 
Colour vision- Normal / Defective 
Central fields: 
 Normal 
 Central scotoma 
 Centro caecal scotoma 
 Altitudinal field defect 
 Generalised contraction 
Brightness sensitivity- Normal / Reduced 
Red desaturation- Normal / Reduced 
Fundus –         
Normal 
Edema 
Hyperemia 
Temporal Pallor 
Primary optic atrophy 
Secondary optic atrophy 
Consecutive optic atrophy 
Macula- 
 
Follow up: 3 months 
Subjective improvement: Yes / No 
Ocular exam:       RE  LE 
UCVA 
BCVA 
Anterior segment-       
Pupil- Normal 
  Sluggish 
           RAPD 
          
EOM- Full / Restricted 
   Painful / Painless 
Colour vision- Normal / Defective 
Central fields: 
 Normal 
 Central scotoma 
 Centro caecal scotoma 
 Altitudinal field defect 
 Generalised contraction 
Brightness sensitivity- Normal / Reduced 
Red desaturation- Normal / Reduced 
Fundus –         
Normal 
Edema 
Hyperemia 
Temporal Pallor 
Primary optic atrophy 
Secondary optic atrophy 
Consecutive optic atrophy 
Macula- 
  
Informed Consent form to participate in a clinical trial 
Study Title: Clinical features and Visual outcome in paediatric 
optic neuritis 
Name of the principal investigator: Dr. R. Uma 
Protocol Number: 
  
Subject’s Name:_______________ 
Subject’s Initials: _______________  
 Subject ID No: _________________ 
Date of Birth / Age: _________________  
  
    Please put 
initial in 
the box 
(Subject) 
(i) I confirm that I have understood the information about the 
study, procedures and treatments for the above study and 
have had the opportunity to ask questions and I received 
satisfactory answers to all of my questions.  I have been 
given a copy of the informed consent form to take home 
[         ] 
(ii) I understand that my participation in the study is voluntary 
and that I am free to withdraw at any time, without giving 
any reason, without my medical care or legal rights being 
affected. However, this is may  not be possible for certain 
surgical procedures  
[         ] 
(iii) I understand that the Investigator of the study to access my 
health records for the research purpose. However, I 
understand that my identity will not be revealed in any 
information released to third parties or published. 
[         ] 
(iv) I agree not to restrict the use of any data or results that 
arise from this study provided such a use is only for 
scientific purpose(s) 
[        ] 
 
(v) I agree to take part in the above study. [         ] 
    
Signature (or Thumb impression) of the Subject: 
_____________________________  
  
 Date: _____/_____/______ 
  
Subject’s Name: __________________________________________ 
  
Signature (or Thumb impression) of Legally Acceptable 
Representative (LAR): 
 
___________________________________________               
Date: ____________  
 
 
Signature of the Investigator: ___________________________ 
Date: _____/_____/______ 
  
Investigator’s Name: ______________________________________ 
  
Signature of the Witness ______________________               
Date:_____/_____/_______  
  
Name of the Witness: ______________________________________ 
 
  
  
Urkund Analysis Result 
Analysed Document: DOC-20171010-WA0002.docx (D31189070)
Submitted: 10/10/2017 4:28:00 PM 
Submitted By: ramaprabha86@gmail.com 
Significance: 1 % 
Sources included in the report: 
final thesis part 1 and 2.docx (D31101627) 
Instances where selected sources appear: 
1 
U R K N DU
 
Name age gender MR no laterality
onset of 
symptoms ucva bcva colour vision defect field defect
pain on eye 
movements headache fever vaccination rapd brightness sensitivity red desaturation fundus imaging bcva - 1 month rapd colour vision central fields
brightness 
sensitivity red desaturation fundus
bcva - 3 
months rapd colour vision central fields
brightness 
sensitivity
red 
desaturation fundus
Bavatharani 6 Female 4228828 BE 2 days RE - HM HM Poor vision Poor vision absent present absent no Ill sustained pupils poor vision Poor vision Disc edema nerves 6/9. absent 19/21 Normal Normal Normal Temporal pallor 6/6. absent 21/21 normal normal normal temporal pallor
LE - HM HM Poor vision Poor vision absent Ill sustained pupils poor vision Poor vision Disc edema 6/9. absent 19/21 Normal Normal Normal Temporal pallor 6/6. absent 21/21 normal normal normal temporal pallor
Uma maheswari 10 Female 4297842 BE 2 days RE-1/2 /60. 1/2 /60. Poor vision Poor vision absent present absent no Ill sustained pupils Reduced Poor vision Disc edema
nerves. Possible 
RBN 6/6. Ill sustained 20/21 Normal Normal Reduced Temporal pallor 6/6. absent 21/21 normal normal normal temporal pallor
LE- 1/2 /60. 1/2 /60. Poor vision Poor vision absent Ill sustained pupils Reduced Poor vision Disc edema 6/6. Ill sustained 20/21 Normal Normal Reduced Temporal pallor 6/6. absent 21/21 normal normal normal temporal pallor
Dhinesh Kumar 9 Male 4358266 RE 2 days 6/18. 6/18. Defective
Centro caecal 
scotoma absent present absent no Present Reduced Reduced Disc edema Possible RBN 6/9. present 20/21 Normal Reduced Reduced Resolving disc edema 6/6. present 21/21 normal normal normal temporal pallor
abdul rahman 10 Male 4384785 LE 3 days 1/60. 1/60. Defective Poor vision absent present present no Present Reduced Poor vision Disc edema nerves 6/9. present 20/21 Normal Reduced Reduced Temporal pallor 6/6. present 21/21 normal normal reduced temporal pallor
siva 10 Male 4401854 BE 3 days RE 3/60. 3/60. Poor vision Poor vision absent absent absent no Ill sustained pupils Reduced Poor vision Disc edema Normal 6/6. absent 21/21 Normal Normal Normal Normal 6/6. absent 21/21 normal normal normal normal
LE HM HM Poor vision Poor vision absent Present Reduced Poor vision Disc edema 6/9p. present 5/21. Normal Reduced Reduced Temporal pallor 6/6p present 19/21 normal normal reduced temporal pallor
Elakkiya 13 Female 4004465 LE 4 days 6/18. 6/18. Defective
Centro caecal 
scotoma absent present absent no Present Reduced Reduced Disc edema Normal 6/9. present 19/21 Normal Reduced Reduced Temporal pallor 6/9. present 21/21 normal normal normal temporal pallor
Krishna Kumar 11 Male 4258537 RE 4 days HM HM Poor vision Poor vision present absent absent no Present poor vision Poor vision Normal Possible RBN/ CIS 6/6p. absent 21/21 Normal Normal Reduced Normal 6/6. absent 21/21 normal normal reduced normal
Mukesh kumar 11 Male 4374953 BE 3 days RE PL PL Poor vision Poor vision present absent absent no Ill sustained pupils poor vision Poor vision Disc edema MS 5/60. Ill sustained 1/21. Normal Reduced Reduced Temporal pallor 6/9p pupils 2/21. normal reduced reduced temporal pallor
LE FCF FCF Poor vision Poor vision present Ill sustained pupils poor vision Poor vision Disc edema 6/36. Ill sustained 1/21. Normal Reduced Reduced Temporal pallor 6/6p pupils 2/21. normal normal reduced temporal pallor
Jerusha 13 Female 4247437 RE 2 days 1/60. 1/60. Poor vision Poor vision present present absent no Present Reduced Poor vision Disc edema Normal 6/9. present 19/21 Normal Reduced Reduced Temporal pallor 6/6p present 21/21 normal normal reduced temporal pallor
Athi sivan 13 Male 3895777 BE 5 days RE 3/60. 3/60. Defective Not  co operative absent present absent no Ill sustained pupils Reduced Poor vision Disc edema Normal 6/12. Ill sustained 20/21 Normal Normal Reduced Temporal pallor 6/6p absent 20/21 normal normal reduced temporal pallor
LE 3/60 3/60. Defective Not  co operative absent present absent no Ill sustained pupils Reduced Poor vision Disc edema 6/6p. Ill sustained 21/21 Normal Normal Reduced Temporal pallor 6/6. absent 21/21 normal normal reduced temporal pallor
Kaveri 13 Female 3979169 LE 2 days HM HM Poor vision Poor vision present absent absent no Present Reduced Poor vision Normal MS 6/9. present 11/21. Normal Reduced Reduced Normal 6/9. present 13/21 normal reduced reduced normal
surya 11 Female 3988822 BE 15 days RE No PL RE No PL No vision No vision absent present present no Ill sustained pupils no vision no vision mild hyperemia chiasmatic HM Ill sustained Poor vision Poor vision Poor vision Poor vision Pale disc FCF pupils Poor vision Poor vision Poor vision Poor vision Pale disc
LE No PL LE No PL No vision No vision absent no vision no vision mild hyperemia HM Ill sustained Poor vision Poor vision Poor vision Poor vision Pale disc HM pupils Poor vision Poor vision Poor vision Poor vision Pale disc
priyadharshini. D 12 Female 4018644 BE 1 day RE 6/6p 6/6p 21/21 normal present present present no absent normal normal Disc edema Possible RBN 6/6. absent 21/21 Normal Normal Normal Normal 6/6. absent 21/21 normal normal normal normal
LE 2/60. 2/60. 0/21 Poor vision present present present no Present Reduced Poor vision Disc edema 6/6. present 21/21 Normal Normal Normal Temporal pallor 6/6. present 21/21 normal normal normal temporal pallor
purna chandra 9 Male 4058694 BE 15 days RE 1/60. 1/60. Poor vision Poor vision absent present absent no Ill sustained pupils poor vision Poor vision temporal pallor Possible RBN HM Ill sustained Poor vision Poor vision Poor vision Poor vision Temporal pallor HM pupils Poor vision Poor vision Poor vision Poor vision temporal pallor
LE 1/60. 1/60. Poor vision Poor vision absent present absent no Ill sustained pupils poor vision Poor vision temporal pallor HM Ill sustained Poor vision Poor vision Poor vision Poor vision Temporal pallor HM pupils Poor vision Poor vision Poor vision Poor vision temporal pallor
manisha 6 Female 4068534 BE 3 days RE 6/36 6/36. 1/21. Not  co operative present present present no Ill sustained pupils Reduced Reduced Normal ? MS 6/9. absent 19/21 Normal Normal Reduced Normal 6/6. absent 20/21 normal normal normal normal
LE 6/36 6/36. 1/21. Not  co operative present present present no Ill sustained pupils Reduced Reduced Normal 6/9. absent 19/21 Normal Normal Reduced Normal 6/6. absent 20/21 normal normal normal normal
Aruna devi 14 Female 4101868 BE 1 day RE 4/60 4/60. 0/21.
Generalised 
constriction absent present absent no Ill sustained pupils Reduced Reduced Normal Possible RBN 6/12. Ill sustained 17/21 Normal Normal Reduced Temporal pallor 6/6. absent 20/21 normal normal normal temporal pallor
LE 4/60 4/60. 0/21.
Generalised 
constriction absent present absent no Ill sustained pupils Reduced Reduced Normal 6/12. Ill sustained 17/21 Normal Normal Reduced Temporal pallor 6/6. absent 20/21 normal normal normal temporal pallor
Parveen 14 Female 4235643 RE 5 days PL PL Poor vision Poor vision present present absent no Present poor vision Poor vision Disc edema Normal 6/36. present 19/21 Normal Reduced Reduced Temporal pallor 6/9. present 21/21 normal normal reduced temporal pallor
Rohitha 6 Female 4305728 RE 4 days PL PL Poor vision Poor vision present present absent no Present poor vision Poor vision Disc edema apex syndrome 6/18. present 11/21. Normal Reduced Reduced Temporal pallor 6/9. present 20/21. normal normal reduced temporal pallor
priyadharshini.S 8 Female 4167590 BE 4 days RE 5/60 5/60. 1/21. Poor vision absent absent absent no Ill sustained pupils Reduced Poor vision Disc edema RBN 6/6. Ill sustained 20/21 Normal Normal Reduced Normal 6/6. absent 21/21 normal normal normal normal
LE PL PL Poor vision Poor vision absent Present Reduced Poor vision Disc edema 6/12. present 17/21 Normal Reduced Reduced Temporal pallor 6/6p pupils 21/21 normal normal reduced temporal pallor
Ramya 5 Female 4087958 BE 2 days RE Fix light Fix light not co operative Not  co operative absent absent absent no Ill sustained pupils not co operative not co operative Disc edema
Thickened optic 
nerves 6/9p. absent not co operative not co operative not co operative not co operative Pale disc 6/9. absent not co operative not co operative not co operative
not co 
operative Pale disc
LE Fix light Fix light not co operative Not  co operative absent Ill sustained pupils not co operative not co operative Disc edema 6/6. absent not co operative not co operative not co operative not co operative Temporal pallor 6/6. absent not co operative not co operative not co operative
not co 
operative temporal pallor
Muthumari 9 Female 4084646 BE 5 days RE 1/60. 1/60. Poor vision Not  co operative absent present absent no Ill sustained pupils Reduced Poor vision Disc edema RBN 6/12. absent 19/21 Normal Reduced Reduced Temporal pallor 6/6p absent 20/21 normal normal reduced temporal pallor
LE 3/60. 3/60. Poor vision Not  co operative absent Ill sustained pupils Reduced Poor vision Disc edema 6/9. absent 20/21 Normal Reduced Reduced Temporal pallor 6/6. absent 21/21 normal normal normal temporal pallor
Kaviya 12 Female 4069595 BE 2 days RE 1/60. 1/60. Poor vision Poor vision absent absent absent no Ill sustained pupils Reduced Poor vision Disc edema possible RBN 6/6. absent 21/21 Normal Normal Normal Normal 6/6. absent 21/21 normal normal normal normal
LE 1/60. 1/60. Poor vision Poor vision absent Present Reduced Poor vision Disc edema 6/6p. absent 20/21 Normal Normal Reduced Temporal pallor 6/6p absent 21/21 normal normal reduced temporal pallor
Thiru Kumaran 9 Male 4069001 BE 1 day RE FCF FCF Poor vision Poor vision absent absent present no Ill sustained pupils Reduced Poor vision Disc edema RBN 3/60. Ill sustained Poor vision defective Reduced Poor vision Pale disc 6/60. absent 1/21. defective reduced reduced Pale disc
LE 5/60 5/60. Poor vision Poor vision absent Ill sustained pupils Reduced Poor vision Disc edema 6/36. Ill sustained 1/21. defective Reduced Reduced Temporal pallor 6/36. absent 1/21. defective reduced reduced temporal pallor
Mani perumal 13 Male 3986605 RE 2 days 1/60. 1/60. Poor vision Poor vision present absent absent no Present Reduced Poor vision Disc edema Normal 6/9. absent 21/21 Normal Normal Reduced Temporal pallor 6/6. absent 21/21 normal normal reduced temporal pallor
LE 6/6. 6/6. 21/21 normal absent normal normal Normal 2/60. present 0/21 Poor vision Reduced Poor vision disc edema 6/9. absent 20/21 normal normal reduced temporal pallor
Prasanna 9 Male 3843754 RE 3 days 1/60. 1/60. Poor vision Poor vision present present absent no Present poor vision Poor vision Disc edema Normal 6/18. present 20/21 Normal Reduced Reduced Temporal pallor 6/9. present 21/21 normal normal reduced temporal pallor
Pulamolu Jashva 13 Male 4135354 RE 3 days 6/36. 6/36. Defective
Generalised 
constriction absent absent absent no Present Reduced Reduced Disc edema RBN 6/9. present 20/21 Normal Normal Reduced Temporal pallor 6/6. present 21/21 normal normal reduced temporal pallor
Vikash maran 11 Male 3957365 RE 2 days 6/36. 6/36. Defective
Generalised 
constriction absent absent absent no Present Reduced Reduced Disc edema Normal 6/9. present 20/21 Normal Reduced Reduced Temporal pallor 6/6p present 21/21 normal normal reduced temporal pallor
Aariffun 10 Male 4175663 RE 3 days 1/60. 1/60. Poor vision Poor vision absent absent present no Present Reduced Poor vision Disc edema Normal 6/12. present 19/21 Normal Reduced Reduced Temporal pallor 6/9. present 21/21 normal reduced reduced temporal pallor
Sandhya Rani 13 Female 4286749 RE 5 days 6/24. 6/24. Defective
Centro caecal 
scotoma absent absent absent no Present Reduced Reduced Disc edema
Thickened optic 
nerves 6/9p. present 20/21 Normal Reduced Reduced Temporal pallor 6/9. present 21/21 normal reduced reduced temporal pallor
Kokila 14 Female 4185749 LE 3 days 1/60. 1/60. Poor vision Poor vision absent absent absent no Present Reduced Poor vision Disc edema Normal 6/18. present 13/21 Normal Reduced Reduced Temporal pallor 6/9. present 21/21 normal reduced reduced temporal pallor
Sindhu 10 Female 4023656 LE 2 days PL PL Poor vision Poor vision absent absent present no Present Reduced Poor vision Disc edema Normal 6/36. present 9/21. Normal Reduced Reduced Temporal pallor 6/9p present 19/21 normal reduced reduced temporal pallor
Vimala 14 Female 4068496 LE 3 days 6/12. 6/12. Defective
Centro caecal 
scotoma absent absent absent no Present Reduced Reduced Disc edema Normal 6/9. present 20/21 Normal Reduced Reduced Temporal pallor 6/9. present 21/21 normal reduced reduced temporal pallor
Manoj 9 Male 4046684 LE 3 days 4/60. 4/60. Defective
Generalised 
constriction absent absent present no Present Reduced Reduced Disc edema
Thickened optic 
nerve 6/12. present 19/21 Normal Reduced Reduced Temporal pallor 6/9. present 21/21 normal reduced reduced temporal pallor
Minna Mathews 11 Female 4187584 RE 2 days 1/60. 1/60. Poor vision Poor vision absent present present no Present Reduced Poor vision Disc edema nerve 6/12. present 20/21 Normal Reduced Reduced Temporal pallor 6/6p present 21/21 normal reduced reduced temporal pallor
Subhashini 9 Female 4027584 RE 3 days 1/60. 1/60. Poor vision Poor vision absent absent present no Present poor vision Poor vision Disc edema Normal 6/18. present 19/21 Normal Reduced Reduced Temporal pallor 6/9. present 21/21 normal reduced reduced temporal pallor
Pandi Meena 12 Female 3975976 RE 2 days 3/60. 3/60. Poor vision Poor vision absent absent present no Present Reduced Poor vision Disc edema nerve 6/12p present 18/21 Normal Reduced Reduced Temporal pallor 6/9. present 21/21 normal reduced reduced temporal pallor
Alagendran 13 Male 3684587 RE 3 days 4/60. 4/60. Defective
Generalised 
constriction absent absent present no Present Reduced Reduced Disc edema Normal 6/12p present 18/21 Normal Reduced Reduced Temporal pallor 6/6p. present 21/21 normal reduced reduced temporal pallor
Sathya Priyan 9 Male 3856357 LE 2 days 1/60. 1/60. Poor vision Poor vision absent absent absent no Present Reduced Poor vision Normal Normal 6/12. present 16/21 Normal Reduced Reduced Temporal pallor 6/9. present 21/21 normal reduced reduced temporal pallor
